Citations

Clear

361 citation(s) found for "Bauer, M".

Exercise Training Attenuates Placental Ischemia-Induced Hypertension and Angiogenic Imbalance in the Rat
Gilbert, Jeffrey S. , Banek, Christopher T. , Bauer, Ashley J., Gingery, Anne , Needham, Karen Wiedenfeld , Gingery, Anne

Mayo Clinic

Hypertension | October 23, 2012 | Volume: 60 | Issue: 6 | Pages: 1545-1551

10.1161/hypertensionaha.112.202275 | PMID 23090773 Get It

An imbalance between proangiogenic (vascular endothelial growth factor) and antiangiogenic (soluble fms-like tyrosine kinase 1) factors plays an important role in hypertension associated with reduced uteroplacental perfusion (RUPP). Exercise has been shown to stimulate proangiogenic factors, such as vascular endothelial growth factor, in both the pregnant and nonpregnant state; thus, we hypothesized that exercise training would attenuate both angiogenic imbalance and hypertension attributed to RUPP. Four groups of animals were studied, RUPP and normal pregnant controls and normal pregnant and RUPP+exercise training. Exercise training attenuated RUPP-induced hypertension ( P <0.05), decreased soluble fms-like tyrosine kinase 1 ( P <0.05), increased VEGF (P<0.05), and elevated the soluble fms-like tyrosine kinase 1:vascular endothelial growth factor ratio. The positive effects of exercise on angiogenic balance in the RUPP rats were confirmed by restoration ( P <0.05) of the RUPP-induced decrease in endothelial tube formation in human umbilical vascular endothelial cells treated with serum from each of the experimental groups. Placental prolyl hydroxylase 1 was increased ( P <0.05) in RUPP+exercise training rats. Decreased trolox equivalent antioxidant capacity in the placenta, amniotic fluid, and kidney of the RUPP rats was reversed by exercise. RUPP-induced increase in renal thiobarbituric acid reactive species was attenuated by exercise. The present data show that exercise training before and during pregnancy attenuates placental ischemia-induced hypertension, angiogenic imbalance, and oxidative stress in the RUPP rat and reveals that increased prolyl hydroxylase 1 is associated with decreased soluble fms-like tyrosine kinase 1, thus revealing several potential pathways for exercise training to mitigate the effects of placental ischemia-induced hypertension. Lastly, the present study demonstrates that exercise training may be a useful approach to attenuate the development of placental ischemia-induced hypertension during pregnancy.
Faculty Opinions recommendation of Evaluation of the botanical authenticity and phytochemical profile of black cohosh products by high-performance liquid chromatography with selected ion monitoring liquid chromatography-mass spectrometry.
Bauer, Brent A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 19, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.13679.471174 Get It

Faculty Opinions recommendation of Improvement in fibromyalgia symptoms with acupuncture: results of a randomized controlled trial.
Bauer, Brent A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 19, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.14414.471916 Get It

Faculty Opinions recommendation of Efficacy and safety of acupuncture for chronic uncomplicated neck pain: a randomised controlled study.
Bauer, Brent A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1040753.489788 Get It

Faculty Opinions recommendation of Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects.
Bauer, Brent A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1048055.499097 Get It

Acupuncture for Treatment of Noncyclic Breast Pain: A Pilot Study
Thicke, Lori A., Hazelton, J, Bauer, Brent A. , Chan, Carl W., Huntoon, Elizabeth, Novotny, Paul J. , Sloan, Jeff A. , Wahner‐Roedler, Dietlind L.

Mayo Clinic

The American Journal of Chinese Medicine | November 14, 2011 | Volume: 39 | Issue: 06 | Pages: 1117-1129

10.1142/s0192415x11009445 | PMID 22083985 Get It

Noncyclic breast pain is a common breast disorder prompting women to seek medical evaluation. We aimed to perform a pilot study on the relief of noncyclic breast pain using acupuncture. Thirty-seven women seen at a diagnostic breast clinic between April 2003 and January 2009 were enrolled. Treatment consisted of four acupuncture sessions over two weeks, with three months of follow-up. Response to treatment was measured with use of a breast pain questionnaire, a quality of life (QOL) questionnaire, and the Cleeland Brief Pain Inventory (BPI) assessed at baseline, end of treatment, and three months after treatment. Data were analyzed using standard descriptive statistics. Twenty-two patients completed four acupuncture sessions. Pain described as throbbing and heavy decreased significantly after acupuncture (p = 0.04 and p = 0.03, respectively). After treatment, pain scores (on the 10-point BPI scale) decreased by an average of 3.5 points for the worst pain during the previous month (p = 0.001), by 2.7 points for average pain (p < 0.001), and by 2.3 points for pain interference (p = 0.002). The percentage of patients reporting a clinically meaningful decrease of 2 points from baseline to the end of treatment included 67% (12/18) for the worst pain, 65% (11/17) for average pain, and 56% (10/18) for pain interference. QOL data showed no improvement in QOL measures (mental, physical, emotional, social, or spiritual well-being). The results of this preliminary study suggest that a randomized controlled trial may be warranted to evaluate the effect of acupuncture on noncyclic breast pain, as well as the optimal frequency of acupuncture treatments.
Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668
Walden, Chad A., Qin, Rui , Ziegler, Katie L. Allen, Haslam, John L., Rajewski, Roger A., Warndahl, Roger, Fitting, Cindy L., Boring, Daniel, Szabó, Éva , Crowell, James A., Perloff, Marjorie , Jong, Ling, Bauer, Brent A. , Mandrekar, Sumithra J. , Ames, Matthew M. , Reid, Joel M. , Limburg, Paul J. , Szabo, Eva

Mayo Clinic

Cancer Prevention Research | March 4, 2011 | Volume: 4 | Issue: 3 | Pages: 347-353

10.1158/1940-6207.capr-10-0313 | PMID 21372034 Get It

Abstract SR13668, an orally active Akt pathway inhibitor, has demonstrated cancer chemopreventive potential in preclinical studies. To accelerate the clinical development of this promising agent, we designed and conducted the first-ever phase 0 chemoprevention trial to evaluate and compare the effects of food and formulation on SR13668 bioavailability. Healthy adult volunteers were randomly assigned to receive a single, 38-mg oral dose of SR13668 in one of five different formulations, with or without food. On the basis of existing animal data, SR13668 in a PEG400/Labrasol oral solution was defined as the reference formulation. Blood samples were obtained pre- and post-agent administration for pharmacokinetic analyses. Area under the plasma concentration–time curve (AUC0–∞) was defined as the primary endpoint. Data were analyzed and compared using established statistical methods for phase 0 trials with a limited sample size. Participants (n = 20) were rapidly accrued over a 5-month period. Complete pharmacokinetic data were available for 18 randomized participants. AUC0–∞ values were highest in the fed state (range = 122–439 ng/mL × hours) and were statistically significantly different across formulations (P = 0.007), with Solutol HS15 providing the highest bioavailability. SR13668 time to peak plasma concentration (3 hours; range, 2–6 hours) and half-life were (11.2 ± 3.1 hours) were not formulation-dependent. Using a novel, highly efficient study design, we rapidly identified a lead formulation of SR13668 for further clinical testing. Our findings support application of the phase 0 trial paradigm to accelerate chemoprevention agent development. Cancer Prev Res; 4(3); 347–53. ©2011 AACR.
Utilisation of Acupuncture at An Academic Medical Centre
Vincent, Ann , Kruk, Kelly M., Cha, Stephen S, Bauer, Brent A. , Martin, David P. , Cha, Stephen S

Mayo Clinic

Acupuncture in Medicine | September 22, 2010 | Volume: 28 | Issue: 4 | Pages: 189-190

10.1136/aim.2010.002568 | PMID 20861401 Get It

Objective To provide information about the clinical use of acupuncture at an academic medical centre in the USA. Methods A retrospective review of 904 patients (receiving 6070 treatments) who were referred for acupuncture treatment at the Mayo Clinic (Rochester, Minnesota, USA) between 1 January 2004 and 31 December 2008. Data gathered included age, sex, primary diagnosis, number of treatments per diagnosis and health insurance carrier. Results The mean (SD) age of the patients was 53.4 (16.2) years; 73.8% were female and 26.2% were male. The three most common diagnostic categories for which acupuncture was used were spinal pain (33.4%), pain (other) (25.1%) and joint pain (12.3%). About 42% of visits were not covered by health insurance carriers and hence patients had to pay themselves. For the remaining 58% of visits, health insurance carriers picked up all or part of the cost of the acupuncture treatments. Conclusion The results indicate that pain is the most common reason for use of acupuncture in an academic medical centre and that women use acupuncture more than men. This is one of the few reports of clinical use of acupuncture at academic medical centres in the USA.
Strategic Plan for Lung Vascular Research: An NHLBI-ORDR Workshop Report
Erzurum, Serpil C. , Rounds, Sharon , Stevens, Troy , Aldred, Micheala A. , Aliotta, Jason M., Asosingh, Kewal, Balaban, Robert S. , Bauer, Natalie , Bhattacharya, Jahar , Bogaard, Harm Jan , Choudhary, Gaurav , Dorn, Gerald W., Dweik, Raed A. , Fagan, Karen, Fallon, Michael B. , Finkel, Toren , Geraci, Mark W. , Gladwin, Mark T. , Humbert, Marc , Kaminski, Naftali , McMurtry, Ivan F., Newman, John H. , Nicolls, Mark R. , Rabinovitch, Marlene , Shizuru, Judy, Oka, Masahiko, Polgàr, Péter , Rodman, David M., Schumacker, Paul T. , Stenmark, Kurt R. , Tuder, Rubin M. , Voelkel, Norbert F., Sullivan, Eugene J., Weinshilboum, Richard M. , Yöder, Mervin C. , Zhao, Yingming , Gail, Dorothy B., Moore, Timothy M. , Archer, Stephen L. , Hassoun, Paul M. , Kawut, Steven M. , Loscalzo, Joseph , McDonald, Donald M. , Weinshilboum, Richard M. , Kaminski, Naftali

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | September 10, 2010 | Volume: 182 | Issue: 12 | Pages: 1554-1562

10.1164/rccm.201006-0869ws | PMID 20833821 Get It

Abstract The Division of Lung Diseases of the National Heart, Lung, and Blood Institute, with the Office of Rare Diseases Research, held a workshop to identify priority areas and strategic goals to enhance and accelerate research that will result in improved understanding of the lung vasculature, translational research needs, and ultimately the care of patients with pulmonary vascular diseases. Multidisciplinary experts with diverse experience in laboratory, translational, and clinical studies identified seven priority areas and discussed limitations in our current knowledge, technologies, and approaches. The focus for future research efforts include the following: (1) better characterizing vascular genotype–phenotype relationships and incorporating systems biology approaches when appropriate; (2) advancing our understanding of pulmonary vascular metabolic regulatory signaling in health and disease; (3) expanding our knowledge of the biologic relationships between the lung circulation and circulating elements, systemic vascular function, and right heart function and disease; (4) improving translational research for identifying disease-modifying therapies for the pulmonary hypertensive diseases; (5) establishing an appropriate and effective platform for advancing translational findings into clinical studies testing; and (6) developing the specific technologies and tools that will be enabling for these goals, such as question-guided imaging techniques and lung vascular investigator training programs. Recommendations from this workshop will be used within the Lung Vascular Biology and Disease Extramural Research Program for planning and strategic implementation purposes.
External Qigong for Chronic Pain
Vincent, Ann , Hill, Jamia, Kruk, Kelly M., Cha, Stephen S., Bauer, Brent A. , Cha, Stephen S.

Mayo Clinic

The American Journal of Chinese Medicine | July 13, 2010 | Volume: 38 | Issue: 04 | Pages: 695-703

10.1142/s0192415x10008160 | PMID 20626055 Get It

External qigong as a pharmacotherapy adjunct was investigated in 50 subjects with chronic pain (pain lasting > 3 months with pain score of ≥ 3 on 0–10 numeric analog scale) who presented to a qigong healing center. Participants were randomized to receive either external qigong treatment (EQT) or equivalent attention time (EAT) in weekly 30-min sessions for four consecutive weeks. Outcomes were assessed before and after sessions. The primary outcome measure was intensity of pain by a 10-cm visual analog scale used to rate all pain severity measurements. At 8-week follow-up, participants were contacted by telephone and mailed a questionnaire. Most had experienced pain for > 5 years (66%); the rest, for > 3 to 5 years (8%), 1 to 3 years (10%), or < 1 year but > 3 months (10%). The most frequent concomitant diagnoses were multifactorial (26%), osteoarthritis (18%), and low back pain (12%). Most patients were also receiving other treatments (74%); none previously had EQT. Participants were randomly assigned to EQT ( n = 26) or EAT ( n = 24). These groups had no significant differences at baseline except for prior awareness of qigong (EQT 31% vs. EAT 63%; p = 0.025). Compared to the EAT group, EQT participants had a significant decrease in pain intensity in the 2nd ( p = 0.003), 3rd ( p < 0.001), and 4th weeks of treatment ( p = 0.003). At week 8, these differences in overall decreased pain intensity persisted but were not statistically significant.